{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:32:02Z","timestamp":1784590322450,"version":"3.55.0"},"reference-count":37,"publisher":"Hindawi Limited","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3701,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2005.00587.x","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T01:34:08Z","timestamp":1121823248000},"page":"969-974","source":"Crossref","is-referenced-by-count":47,"title":["Pimecrolimus in dermatology: atopic dermatitis and beyond"],"prefix":"10.1155","volume":"59","author":[{"given":"Paolo","family":"Gisondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2005,7,14]]},"reference":[{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB1|cit1","first-page":"618","article-title":"The macrolide immunosuppressants in dermatology: mechanisms of action","volume":"12","author":"Marsland","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.0906-6705.2004.00269.x","article-title":"Pimecrolimus - an anti-inflammatory drug targeting the skin","volume":"13","author":"Grassberger","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1742-1241.2003.tb10492.x","article-title":"Pimecrolimus: a review of pre-clinical and clinical data","volume":"57","author":"Graham-Brown","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.0022-202X.2004.22324.x","article-title":"Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells","volume":"122","author":"Hoetzenecker","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1365-2249.2003.02225.x","article-title":"Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids","volume":"133","author":"Kalthoff","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1067\/mai.2001.112600","article-title":"Human epidermal Langherans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)","volume":"107","author":"Panhans-Gross","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB7|cit7","first-page":"231","article-title":"Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity in contrast to tacrolimus and cyclosporine A","volume":"121","author":"Meingassner","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2133.2001.04076.x","article-title":"The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study","volume":"144","author":"Queille-Roussel","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijpharm.2003.07.013","article-title":"Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than CS and tacrolimus","volume":"269","author":"Billich","year":"2004","journal-title":"Int J Pharmacol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0140-6736(03)12193-9","article-title":"Atopic dermatitis","volume":"361","author":"Leung","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1034\/j.1398-9995.2003.00112.x","article-title":"The epidemiology of atopic dermatitis in Italian schoolchildren","volume":"58","author":"Girolomoni","year":"2003","journal-title":"Allergy"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.18553\/jmcp.2002.8.5.333","article-title":"The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization","volume":"8","author":"Fivenson","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1067\/mjd.2002.120528","article-title":"Cost of atopic dermatitis and eczema in the United States","volume":"46","author":"Ellis","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mjd.2002.122187","article-title":"Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents","volume":"46","author":"Eichenfield","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-4632.2004.02234.x","article-title":"Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome","volume":"44","author":"Eichenfield","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaci.2004.05.037","article-title":"Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis","volume":"114","author":"Leo","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jaad.2004.01.051","article-title":"A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis","volume":"51","author":"Kempers","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1067\/mai.2002.126500","article-title":"Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug","volume":"110","author":"Kapp","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaad.2004.09.016","article-title":"Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study","volume":"52","author":"Papp","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000078462","article-title":"Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis","volume":"208","author":"Meurer","year":"2004","journal-title":"Dermatology"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09546630410033781","article-title":"Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis","volume":"15","author":"Luger","year":"2004","journal-title":"J Dermatol Treat"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2133.1997.tb03788.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology","volume":"137","author":"Meingassner","year":"1997","journal-title":"Br J Dermatol"},{"issue":"1 Part 1","key":"10.1111\/j.1368-5031.2005.00587.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1542\/peds.110.1.e2","article-title":"Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children","volume":"110","author":"Wahn","year":"2002","journal-title":"Pediatrics"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2004.08.046","article-title":"Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination","volume":"52","author":"Papp","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2004.06.010","article-title":"Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study","volume":"51","author":"Gribetz","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2133.2004.06208.x","article-title":"Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial","volume":"151","author":"Rigopoulos","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB27|cit27","first-page":"31","article-title":"Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis","volume":"73","author":"Belsito","year":"2004","journal-title":"Cutis"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.0007-0963.2004.05875.x","article-title":"Treatment of oral lichen planus with topical pimecrolimus 1% cream","volume":"150","author":"Esquivel-Pedraza","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.0007-0963.2004.05884.x","article-title":"Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus","volume":"150","author":"Dissemond","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2004.01.044","article-title":"Pimecrolimus 1% cream for cutaneous lupus erythematosus","volume":"51","author":"Kreuter","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB31|cit31","first-page":"563","article-title":"Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus","volume":"3","author":"Lim","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000073099","article-title":"Repigmentation of vitiligo with pimecrolimus cream: a case report","volume":"207","author":"Mayoral","year":"2003","journal-title":"Dermatology"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaad.2004.02.010","article-title":"Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus","volume":"50","author":"Ziemer","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/00015550310003791","article-title":"An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion","volume":"83","author":"Mrowietz","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000070939","article-title":"Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study","volume":"207","author":"Thaci","year":"2003","journal-title":"Dermatology"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1046\/j.1523-1747.2002.00694.x","article-title":"Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated","volume":"119","author":"Rappersberger","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00587.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","article-title":"A new system for grading recommendations in evidence based guidelines","volume":"323","author":"Harbour","year":"2001","journal-title":"BMJ"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2005.00587.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2005.00587.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T23:20:17Z","timestamp":1706397617000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2005.00587.x"}},"subtitle":["Pimecrolimus in Dermatology"],"short-title":[],"issued":{"date-parts":[[2005,7,14]]},"references-count":37,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00587.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7,14]]}}}